Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 

The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.

Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.

The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.

The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.

The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.

Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study.

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.

Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.

Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy.

Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions.

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.

The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data.

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.